N	Concordance
1	ry cell leukemia and chronic myelocytic leukemia. Interleukin 2 (IL-2) is anothe
2	tients with relapsed chronic myelocytic leukemia after allogeneic bone marrow tr
3	n the progression of chronic myelocytic leukemia (CML), we performed allelotype 
4	               for chronic myelogeneous leukemia. Only two Hodgkin's diseases   
5	s carried out on 13 chronic myelogenous leukemia (CML) patients to study the p53
6	nearly all cases of chronic myelogenous leukemia have a consistent mutated gene 
7	or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year 
8	 from a Ph-positive chronic myelogenous leukemia (CML) patient. Using reverse an
9	 to the blast crisis of chronic myeloid leukemia. During this phase, the growth 
10	hia chromosome-positive chronic myeloid leukemia (CML), three acute lymphoblasti
11	ha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant int
12	, chronic myelocytic or chronic myeloid leukemia. Before describing the disease 
13	hocytic leukemia (ALL), chronic myeloid leukemia (CML), and acute myeloid leukem